I've mentioned many times that their sales and management costs are completely out of whack while their therapeutic research is where the money should be spent..
The bull case is essentially the same as ever: that Daxxify is the best botulinum toxin on the market and that RVNC will make a lot of money in due course. Compared to the original bull case, the only change is that it the initial sales ramp was hindered by RVNC’s overpricing the product, and hence it will take longer for the thesis to play out.
News 
Market Data 
Discover 
